Results 81 to 90 of about 2,703,409 (308)

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

, 2020
Outline - Definitions Total Neoadjuvant Therapy (TNT): delivery of chemoradiation and chemotherapy in the neoadjuvant setting Locally advanced rectal cancer: stage II (T3, T4N0) or stage III (Tany, N1/N2) - Introduction Evolution of Rectal Cancer ...
Stem, MD, Jonathan
core   +1 more source

Placement of a self-expandable metallic stent as a bridge to surgery for large bowel obstruction induced by effective neoadjuvant therapy: report of three cases

Surgical Case Reports, 2018
Background Self-expandable metallic stent placement is a widely performed palliative procedure or bridge to surgery for obstructive colorectal cancer. However, the feasibility of this procedure for large bowel obstruction induced by effective neoadjuvant
Fumihiko Ando, Akihisa Matsuda, Masao Miyashita, Satoshi Matsumoto, Nobuyuki Sakurazawa, Youichi Kawano, Hiroshi Yoshida   +6 more
doaj   +1 more source

CHST1 Drives Immunotherapy Resistance in Triple‐Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF–CCL20–Macrophage Axis

Advanced Science, EarlyView.
Proposed model of CHST1‐associated immune remodeling in triple‐negative breast cancer. In CHST1‐low tumors, greater nuclear accumulation of NKRF is associated with repression of an NF‐κB‐related CCL20 transcriptional program and an immune‐inflamed microenvironment.
Shu‐Hao Jiang, Xiao‐Han Ying, Ruo‐Qing Wang, Qun Zhang, Li Chen, Zhi‐Ming Shao, Jun‐Jie Li   +6 more
wiley   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

Advanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang, Dan‐yun Ruan, Jing Shi, Yue Huang, Hui Sheng, Ya‐ling Huang, Linjie Ma, Lijun Wang, Caiwei Chen, Yixuan Wang, Yue Zhang, Yi Shen, Qing Zhang, Jianjian Zhang, Yanfang Tang, Jin‐ling Zhang, Jia‐jia Hu, Chen‐yi Wu, Jia‐ying Chen, Xun Meng, Shu‐Hui Liu, Feng Wang   +21 more
wiley   +1 more source

Neoadjuvant therapy

Journal of the Chinese Medical Association, 2023
Wang, Peng-Hui, Yang, Szu-Ting, Liu, Chia-Hao   +2 more
openaire   +3 more sources

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

, 2022
(1) Background: Neoadjuvant therapy is the main therapeutic strategy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, and the combination of trastuzumab and pertuzumab (HP) has become a routine treatment.
Jingming Ye, Ling Xu, Shuang Zhang, Chen Ye, Xuening Duan, Ling Xin, Hong Zhang, Qian Liu, Yuanjia Cheng, Yinhua Liu, Jiayi Li   +10 more
core   +1 more source

Epigenetic Reactivation of TNFRSF19 Suppresses Mitophagy and Sensitizes Triple‐Negative Breast Cancer to Doxorubicin

Advanced Science, EarlyView.
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu, Chenguang Liu, Weihong Zheng, Xiaofei Tong, Zhengwei Gui, Zonghong Lu, Sun Ieong, Lin Zhang   +7 more
wiley   +1 more source

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER

Сибирский онкологический журнал, 2018
More than 70 % of patients with breast cancer have estrogen-receptor-positive tumors (ER+) and are considered hormone- sensitive. That is why a vast majority of patients with early operable  tumors receive adjuvant endocrine therapy.
V. F. Semiglazov, V. V. Semiglazov, G. A. Dashyan, P. V. Krivorotko, V. G. Ivanov, E. K. Zhiltsova, R. M. Paltuev, L. M. Bershtein, T. Yu. Semiglazova, S. S. Yerechshenko, V. V. Klimenko, V. S. Apollonova, A. V. Komyahov, A. A. Bessonov   +13 more
doaj   +1 more source

NEOADJUVANT THERAPY FOR PROSTATIC CANCER

The Japanese Journal of Urology, 1993
Neoadjuvant therapy for prostatic cancer might be important to increase cure rates of the disease and preservability of the organs. There were 43 cases in a period of 1975-1990 in which total prostatectomy were performed after neoadjuvant therapy. According to the clinical stage, there were 14 cases in B, 23 in C, 4 in D1 and 2 in D2.
Maeda, Osamu, Saiki, Shigeru, Kinouchi, Toshiaki, Kuroda, Masao, Miki, Tsuneharu, Usami, Michiyuki, Kotake, Toshihiko   +6 more
openaire   +3 more sources

Radiation‐Triggered Chemokine‐Secreting Probiotics for Boron Neutron Capture Therapy Based Radioimmunotherapy

Advanced Science, EarlyView.
Engineered Escherichia coli Nissle 1917 with a tannic acid‐mediated BPA coating enables tumor‐targeted boron delivery for BNCT. The low‐level incidental radiation generated during BNCT activate a RecA‐driven circuit to induce CXCL10, while radiation‐enhanced bacterial colonization triggers in situ vaccination and systemic antitumor immunity.
Yang Liu, Yuzhong Qian, Shaobo Huang, Bingbing Li, Yue Yu, Xiang Cheng, Chang Chen, Jiheng Wang, Maosong Yang, Lizheng Liang, Xiancai Meng, Zhigang Liu   +11 more
wiley   +1 more source